| Recruiting | A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thro NCT07194850 | argenx | Phase 2 / Phase 3 |
| Completed | Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP) NCT06287567 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Active Not Recruiting | An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias NCT05757570 | Alpine Immune Sciences, Inc. | Phase 1 / Phase 2 |
| Completed | Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients NCT05492409 | AO GENERIUM | Phase 3 |
| Completed | Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP NCT05220878 | AO GENERIUM | Phase 3 |
| Completed | A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788 NCT04132050 | Kissei Pharmaceutical Co., Ltd. | Phase 3 |
| Unknown | Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind? NCT04128358 | Assiut University | N/A |
| Recruiting | Safety and Efficacy of Fecal Microbiota Transplantation NCT04014413 | Chinese University of Hong Kong | N/A |
| Completed | Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level NCT03864796 | Assiut University | — |
| Unknown | Investigation on a Dynamic Cohort of Italian Patients With Active ITP NCT03465020 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Completed | The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP. NCT03412188 | Nayera Hazaa Elsherif | N/A |
| Completed | Study of Platelets Sialylation by Flow Cytometry for the Differential Diagnosis of ICT NCT03421392 | Nantes University Hospital | — |
| Completed | Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thromb NCT03222843 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Unknown | Assessment of Quality of Life of Children With Chronic Idiopathic Thrombocytopenic Purpura (Kid's ITP Tools) NCT03123497 | University Hospital, Angers | — |
| Withdrawn | MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in S NCT01609452 | Anthera Pharmaceuticals | Phase 2 / Phase 3 |
| Withdrawn | Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients W NCT01443351 | Zealand University Hospital | — |
| Completed | Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases NCT01988506 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurolo NCT01931644 | Sanguine Biosciences | — |
| Withdrawn | All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of NCT01882127 | Shandong University | Phase 3 |
| Withdrawn | Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatm NCT01734057 | Shandong University | Phase 3 |
| Completed | rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP NCT01734044 | Shandong University | Phase 3 |
| Completed | Hemostasis in Patients With Idiopathic Thrombocytopenic Purpura NCT01571349 | Samsung Medical Center | — |
| Terminated | A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExt NCT01433978 | Eisai Inc. | Phase 3 |
| Completed | Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platele NCT01520909 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients NCT01444417 | Amgen | Phase 3 |
| Completed | A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501 NCT01549054 | Eisai Inc. | Phase 1 |
| Completed | rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP NCT01525836 | Shandong University | Phase 3 |
| Unknown | Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP NCT01805648 | Peking Union Medical College | Phase 3 |
| Completed | Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim NCT01143038 | Amgen | Phase 2 |
| Withdrawn | Single Incision Versus Standard Laparoscopic Splenectomy NCT01276561 | Children's Mercy Hospital Kansas City | N/A |
| Completed | Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated W NCT00907478 | Amgen | Phase 4 |
| Completed | Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) NCT01506414 | Ming Hou | Phase 3 |
| Completed | Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag NCT00888901 | Ingrid Pabinger, MD | Phase 4 |
| Completed | Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias NCT00749112 | Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 / Phase 3 |
| Completed | Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP) NCT00828750 | GlaxoSmithKline | Phase 3 |
| Completed | IGIV Study for Chronic ITP Patients Ages 3-70 NCT00511147 | Grifols Biologicals, LLC | Phase 3 |
| Completed | P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopat NCT00603642 | Amgen | Phase 3 |
| Completed | Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects NCT00515203 | Amgen | Phase 1 / Phase 2 |
| Completed | Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study NCT00625443 | Eisai Inc. | Phase 2 |
| Completed | A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. NCT00475423 | Hoffmann-La Roche | Phase 2 |
| Completed | Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura NCT00415532 | Amgen | Phase 3 |
| Completed | Sirolimus for Autoimmune Disease of Blood Cells NCT00392951 | Children's Hospital of Philadelphia | Phase 1 / Phase 2 |
| Completed | Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura NCT00454857 | Amgen | — |
| Completed | High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP NCT00451594 | Cooperative Study Group A for Hematology | Phase 3 |
| Completed | Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology NCT00861224 | Amgen | — |
| Terminated | Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP) NCT00244257 | Genzyme, a Sanofi Company | Phase 1 |
| Completed | A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thro NCT00770562 | Hoffmann-La Roche | Phase 3 |
| Completed | AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior t NCT00102336 | Amgen | Phase 3 |
| Completed | AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refract NCT00102323 | Amgen | Phase 3 |
| Completed | An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP NCT00508820 | Amgen | Phase 3 |
| Completed | Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D NCT00128882 | University of Aarhus | Phase 2 |
| Completed | Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura NCT01713855 | Neufeld, Ellis J, MD, PhD | N/A |
| Completed | The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Id NCT00909077 | Copenhagen University Hospital at Herlev | Phase 3 |
| Completed | Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thro NCT00116688 | Amgen | Phase 3 |
| Completed | Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocy NCT00111475 | Amgen | Phase 2 |